Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab-, Talquetamab- and JNJ-79635322-based Combinations in Newly Diagnosed Transplant-Eligible Multiple Myeloma
2024-517382-17-00Phase 2Authorised
- Sponsor
- Heidelberg University Hospital
- Start
- Sep 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of teclistamab, talquetamab and ramantamig in multiple myeloma (MM) (12 arms), sponsored by Heidelberg University Hospital. Planned start Sep 2024; status: authorised.
02
Drugs
teclistamabtalquetamabramantamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-517382-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517382-17-00.